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Abstract
Cell adhesion is tightly regulated by specific molecular interactions and detachment from the extracellular matrix modifies
proliferation and survival. HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) is a protein-lipid complex with
tumoricidal activity that also triggers tumor cell detachment in vitro and in vivo, suggesting that molecular interactions
defining detachment are perturbed in cancer cells. To identify such interactions, cell membrane extracts were used in Far-
western blots and HAMLET was shown to bind a-actinins; major F-actin cross-linking proteins and focal adhesion
constituents. Synthetic peptide mapping revealed that HAMLET binds to the N-terminal actin-binding domain as well as the
integrin-binding domain of a-actinin-4. By co-immunoprecipitation of extracts from HAMLET-treated cancer cells, an
interaction with a-actinin-1 and -4 was observed. Inhibition of a-actinin-1 and a-actinin-4 expression by siRNA transfection
increased detachment, while a-actinin-4-GFP over-expression significantly delayed rounding up and detachment of tumor
cells in response to HAMLET. In response to HAMLET, adherent tumor cells rounded up and detached, suggesting a loss of
the actin cytoskeletal organization. These changes were accompanied by a reduction in b1 integrin staining and a decrease
in FAK and ERK1/2 phosphorylation, consistent with a disruption of integrin-dependent cell adhesion signaling. Detachment
per se did not increase cell death during the 22 hour experimental period, regardless of a-actinin-4 and a-actinin-1
expression levels but adherent cells with low a-actinin levels showed increased death in response to HAMLET. The results
suggest that the interaction between HAMLET and a-actinins promotes tumor cell detachment. As a-actinins also associate
with signaling molecules, cytoplasmic domains of transmembrane receptors and ion channels, additional a-actinin-
dependent mechanisms are discussed.
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Introduction
Cell adhesion is essential for tissue integrity and processes that
modify adhesion are tightly regulated [1]. In normal cells,
disrupted adhesion attenuates nutrient and growth factor access
and may activate cell death [1,2]. Cancer cells, in contrast, are
frequently able to grow in an anchorage-independent way and
detachment from the site of primary tumor growth may constitute
a first step in metastatic spread. The detachment process requires
complex modifications of molecular interactions in specific
intercellular adhesion complexes as well as with the extracellular
matrix through focal adhesion complexes [3], with key compo-
nents including integrins and proteins linking the integrins to the
cytoskeleton such as a-actinin, talin, tensin, filamin, vinculin and
paxillin. In addition, a wide range of proteins modifies cell
adhesion complexes by controlling the structure or activation state
of their constituents [4].
a-Actinin functions as a scaffold between actin filaments and b
integrins. Actin binds to the N-terminal domains of the anti-
parallel a-actinin homodimer and b integrins recognize the
spectrin-like repeats [4,5,6,7]. So far, four human a-actinin
isoforms have been described. a-Actinin-1 is found in focal
adhesions and various F-actin-based structures [8,9,10]. a-Actinin-
2 and a-actinin-3 are expressed in cardiac and/or skeletal muscles
and cross-link F-actin in the region of Z-discs of muscle cells [11].
a-Actinin-4, which displays 87% sequence identity to a-actinin-1
[9], is detected at points of cell-cell contact [12] and interacts with
focal adhesion constituents, including vinculin and the cytoplasmic
domain of b integrins [3,6,10]. a-Actinin has been proposed to
play a crucial role in the step of de-adhesion e.g. by recruiting
MEKK1 and calpains which cleave several focal adhesion proteins
(reviewed in [13]). In addition, a-actinin-4 deficient cells detach
more easily in response to shear stress than cells with physiological
a-actinin-4 expression, further suggesting a role in cell adhesion
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17179[14]. Furthermore, it has been shown that inhibition of a-actinin-4
by shRNA decreased cell-matrix adhesion in some astrocytoma
cell lines while a-actinin-1 silencing had no effect or even
increased the adhesion [15]. In addition to their role as actin
cross-linkers, a-actinins associate with signaling molecules, cyto-
plasmic domains of transmembrane receptors and ion channels,
connecting the cytoskeletal scaffold to diverse signaling processes
[16].
HAMLET is a complex consisting of partially unfolded a-
lactalbumin and oleic acid, which kills tumor cells and immature
cells but not normal differentiated cells [17]. Early in vitro
experiments showed that HAMLET displays broad anti-tumor
activity [18,19]. Subsequent therapeutic studies have supported
these findings and suggested that HAMLET retains its tumoricidal
activity in vivo. Topical HAMLET administration reduced lesion
size in patients with skin papillomas [20] and HAMLET treatment
delayed tumor progression and increased survival in a rat
glioblastoma xenograft model without evidence of cell death in
healthy brain tissue [21]. In patients with bladder cancer, local
HAMLET instillations killed tumor cells but not healthy cells in
surrounding tissues. During the bladder cancer study, we observed
that HAMLET triggered massive shedding of dead tumor cells
into the urine, suggesting that HAMLET might perturb tumor cell
adhesion in vivo by targeting cell adhesion molecules and their
regulatory pathways [20].
In the present study, we have characterized the detachment
process in greater detail. We identify a-actinin-1 and -4 as
molecular targets for HAMLET and show that interference with
a-actinin function promotes detachment. Tumor cell detachment
in response to HAMLET is accompanied by disruption of
cytoskeletal structure and reduced focal adhesion kinase (FAK)
phosphorylation and MAPK/ERK kinase (MEK)/extracellular-
signal regulated kinase 1/2 (ERK1/2) signaling. The modification
by HAMLET of cell morphology and adherence was carcinoma
cell-specific, as normal differentiated cells remained adherent and
retained their morphology in the presence of HAMLET.
Materials and Methods
HAMLET production
HAMLET was produced as previously described [17]. Briefly,
a-lactalbumin was purified from human milk by hydrophobic
interaction chromatography. The protein was unfolded with
EDTA and subjected to ion-exchange chromatography on a
matrix pre-conditioned with oleic acid and eluted with high salt.
HAMLET was lyophilized after purification and stored at -20uC
until used.
Cellular assays
Lung carcinoma cells (A549, ATCC, Manassas, VA) were
cultured in RPMI-1640 with non-essential amino acids (1:100),
1 mM sodium pyruvate (all from PAA, Pasching, Austria), 50 mg/
ml Gentamicin (Gibco, Paisley, UK) and 5% fetal calf serum
(FCS). Primary cultures of human renal tubular epithelial cells
(HRTEC, [22]) were cultured in DMEM (F12, PAA) with 15%
FCS. Cells (5*10
5/ml for cells in suspension, 40000 cells/well for
adherent cells) were incubated with HAMLET in serum-free
RPMI-1640 at 37uC. FCS was added after 1 hour. Cell death was
quantified by trypan blue exclusion (Chroma Gesellschaft Schmid
& Co, Mu ¨nster, Germany) or by ATP measurements (ATPlite Kit,
PerkinElmer, Waltham, MA, LUMIstar Luminometer, BMG
LABTECH, Offenburg, Germany or Infinite F200, Tecan Group
Ltd., Ma ¨nnedorf, Switzerland).
Blots and co-immunoprecipitation
Proteins were extracted from A549 cells, separated with the
Qproteome Cell Compartment kit (QIAGEN, Hilden, Germany)
into cytosolic, nuclear and cytoskeletal fractions and a fraction
with membrane and membrane-enclosed organelles. Membrane
fractions (10 mg) were subjected to SDS-PAGE on 4–12% Bis-Tris
gels (Invitrogen, Carlsbad, CA). One gel was stained with
Coomassie and a parallel gel was blotted onto PVDF membranes.
After saturation of the membranes (Sat-1 and Sat-2, [23]), the
blots were incubated overnight with HAMLET dissolved in NN8
buffer (5 g/l gelatine hydrolysate, 1 g/l Tween-20, 20.5 g/l NaCl,
0.24 g/l Tris Base, pH 8.7) to 142 mM. Bound HAMLET was
detected using anti-bovine a-lactalbumin antibodies (1:16000,
Bethyl Laboratories, Montgomery, TX), with horseradish perox-
idase-conjugated donkey anti-goat secondary antibodies (1:5000,
Santa Cruz Biotechnology, Santa Cruz, CA), ECL Plus Western
Blotting Reagent (GE Healthcare, Little Chalfont, UK) and
GelDoc equipment (Bio-Rad Laboratories, Hercules, CA). After
identification of the HAMLET-binding proteins, the correspond-
ing bands were excised from the gel, digested and identified by
MALDI-TOF mass spectrometry (Reflex
TM III MALDI-TOF
mass spectrometer (Bruker Daltonics, Bremen, Germany)) and a
ProFound search (http://prowl.rockefeller.edu/, Rockefeller Uni-
versity).
For Western blots for siRNA experiments, the cells were
detached and the same number of cells from each sample was
lysed in NP-40 buffer (50 mM Tris-HCl, pH 7.8, 1% NP-40,
2 mM EDTA, 150 mM NaCl) containing Complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). For
FAK and ERK1/2 Western blots, adherent cells were washed with
PBS containing 0.2 mM PMSF, 1 mg/ml Pepstatin A, 5 mg/ml
Leupeptin (Sigma-Aldrich, St. Louis, MO) and Complete protease
inhibitor cocktail. RIPA lysis buffer [24] containing the same
protease inhibitors was added to the wells and the cells were
removed from the plates using cell scrapers. As a control, some
cells were detached with versen (EDTA) and lysed. The lysates
where cleared by centrifugation and protein concentrations were
measured using the DC Protein Assay (Bio-Rad Laboratories).
Equal amounts of protein or, for siRNA experiments, equal
volumes of lysates were separated by SDS-PAGE on 4-12% Bis-
Tris gels (Invitrogen) and blotted onto PVDF membranes.
Membranes were saturated with BSA (a-actinin-1 and -4,
GAPDH) or nonfat dry milk (phospho-FAK, FAK, phospho-
ERK1/2, ERK1/2, b1 integrin) and incubated with anti-a-
actinin-4 (1:2000, Alexis Biochemicals, San Diego, CA), anti-a-
actinin-1 (1:300, Abcam, Cambridge, UK; 1:2000, Epitomics,
Burlingame, CA), anti-FAK, anti-phospho-Y397-FAK (both
1:1000, BD Biosciences, San Jose, CA), anti-p44/42, anti-
phospho-(Thr202/Tyr204)-ERK1/2 (both 1:1000, Cell Signaling
Technology, Danvers, MA), anti-b1 integrin (1:500, Epitomics) or
anti-GAPDH (1:3000–5000, Novus Biologicals, Littleton, CO)
antibodies, followed by horseradish peroxidase-conjugated sec-
ondary anti-rabbit (1:1000–2000, DakoCytomation, Glostrup,
Denmark) or anti-mouse (1:20000–50000, Novus Biologicals)
antibodies. Bound antibodies were detected with ECL Plus
Western Blotting Reagent (GE Healthcare) and GelDoc equip-
ment (Bio-Rad Laboratories). If required, membranes were
stripped with Restore Western Blot Stripping Buffer (Pierce,
Rockford, IL), reblocked and reprobed with new antibodies.
For co-immunoprecipitation, HAMLET-treated cells were lysed
in Brij 96 [25] (b1 integrin) or NP-40 lysis buffer (a-actinin-1 and -
4) supplemented with Complete protease inhibitor cocktail.
Lysates were incubated with rec-Protein G-SepharoseH 4B beads
(Invitrogen) to reduce unspecific binding. Anti-a-lactalbumin
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antibodies (25 mg/ml, Santa Cruz Biotechnology, Santa Cruz,
CA) were then added to half of the lysate, using the second half as
a control and incubated with gentle agitation at 4uC. After 1 hour,
fresh rec-Protein G-SepharoseH 4B beads were added and the
incubation continued overnight. Beads with bound proteins were
collected by centrifugation (120006g, 30 sec) and washed three
times in lysis buffer. The proteins were recovered by boiling the
beads in LDS sample buffer (Invitrogen) with 100 mM DTT and
used for Western blot.
Peptide-binding assay
Maxi Sorp 96-well plates (NUNC A/S, Roskilde, Denmark)
coated with HAMLET (2 mg/ml) were incubated with biotinylated
a-actinin-4 peptides (200 ng/ml), 20 amino acids long with a 5
amino acid overlap (Innovagen, Lund, Sweden). Bound peptides
were detected with streptavidin-alkaline phosphatase conjugate
(1:1000, Mabtech, Stockholm, Sweden) and phosphatase substrate
(Sigma Aldrich) in 1M diethanolamine pH 9.8 at 405 nm. The
PDB file of cryo-EM determined smooth muscle a-actinin from
chicken gizzard (PDB code 1SJJ; [26]) was used for structural
representation of the protein using MolMol [27].
Immunostaining
For confocal microscopy, cells grown overnight on 8-well
chamber slides (Nalge Nunc, Rochester, NY) were treated with
HAMLET (10% was labeled with Alexa-Fluor 568 (Molecular
Probes, Eugene, OR)) in serum-free medium and fixed in 3.7%
formaldehyde. Detached cells where centrifuged onto microscope
slides. All cells were permeabilized (0.25% Triton X-100/5%
FCS/phosphate buffered saline, 10 minutes) and stained with anti-
a-actinin-4 (1:250, Alexis Biochemicals) or anti-b1 integrin (1:100,
Abcam) antibodies followed by Alexa-Fluor 488-labeled secondary
anti-rabbit antibodies or Alexa-Fluor 568-labeled secondary anti-
mouse antibodies (1:100, Molecular Probes). Nuclei were stained
using DRAQ5 (eBioscience, San Diego, CA). For the peptide
inhibition studies, equimolar amounts of HAMLET and peptide
were pre-incubated for 1 hour before being added to the cells.
Images were captured on a LSM510 META confocal microscope
(Carl Zeiss, Jena, Germany). Fluorescence was detected with
pinhole settings corresponding to 1 airy unit.
For live cell imaging, nuclei were stained with Hoechst 33342
(Invitrogen) before HAMLET (21 mM) was added. The cells were
kept at 37uC, 5% CO2 and examined unfixed in a LSM510 DUO
confocal microscope (Carl Zeiss).
Cell detachment
A549 cells were allowed to adhere overnight (40 000 cells/well
in a 24-well plate). Increasing cell numbers were plated as a
standard curve. The wells were washed with PBS and new
medium without FCS was added together with HAMLET. For
time points longer than 1 hour, FCS was added after 1 hour. The
number of cells present in the well was quantified by measuring
the hexosaminidase activity [28] in each well. Briefly, the medium
was removed, the wells washed with PBS and the hexosaminidase
substrate [28] was added. After 2 hours of incubation at 37uC,
60 ml sample was mixed with 90 ml STOP solution [28] and the
absorbance was measured at 405 nm.
Phase Holographic Imaging
The HoloMonitor
TM M2 digital holographic microscope (Phase
Holographic Imaging AB, Lund, Sweden) records 3D information
of cells using interfering wave fronts induced by the exposure to a
0.8 mW HeNe laser (633 nm), resembling a Mach-Zender
interferometer where the cells, placed in one of the interfering
wave fronts, induce a phase difference between the two beams
[29,30,31]. The interference pattern (hologram) is recorded on a
digital sensor and is used to reconstruct the amplitude and phase of
the object as described [32,33]. Cells grown on m-Slide I coated
with ibiTreat (ibidi, Martinsried, Germany) were treated with
HAMLET and images were captured with an imaging time of 2.4
msec.
Transfections
A549 cells were transfected with a-actinin-4 siRNA (sense sequence
GCAGCAUCGUGGACUACAATT), a-actinin-1 siRNA (sense
sequence CACCAUGCAUGCCAUGCAA) or AllStar Negative
Control siRNA (all from QIAGEN). Cells were grown in 24-well
plates and Lipofectamine 2000 (Invitrogen) was used as a transfection
agent. Knockdown after 72 hours was confirmed by Western blots and
RT-PCR.
For a-actinin-4 overexpression, A549 cells (3610
5) were seeded
in 35-mm glass-bottom dishes (MatTek, Ashland, MA) and
transfected with an a-actinin-4-GFP or a GFP plasmid (Geneco-
poeia, Rockville, MD) using FuGene 6 Transfection Reagent
(Roche Diagnostics).
RT-PCR
RNA was prepared with the RNeasy Mini kit (QIAGEN) and
treated with DNAse I (QIAGEN). cDNA was synthesized using
the Superscript III first strand RT-PCR system (Invitrogen) with
oligo-dT primers. Real-time PCR was performed on a Rotorgene
2000 instrument (Corbett Life Science, Sydney, Australia) using a-
actinin-4 or a-actinin-1 QuantiTect Primer assays (QIAGEN) and
a GAPDH assay (Applied Biosystems, Foster City, CA).
F-Actin binding assay
An actin binding protein spin down assay kit (Cytoskeleton,
Denver, CO) was used according to the manufacturer’s instruc-
tions. Briefly, non-muscle actin was allowed to polymerize into F-
actin. HAMLET was mixed with a-actinin from rabbit skeletal
muscle in a 10:1 molar ratio and incubated for 30 minutes. a-
Actinin with or without HAMLET was mixed with actin and
incubated for 30 minutes. F-Actin was isolated using centrifugation
at 150 0006g for 1.5 hours at 24uC. The supernatant was
removed and the pellet was dissolved in water. To the
supernatants 6 ml 1M DTT and 12 ml LDS sample buffer
(Invitrogen) was added and to the pellets 4 ml 1M DTT and
10 ml LDS sample buffer was added. The samples (20 ml of the
supernatants and 15 ml of the pellets) were separated by SDS-
PAGE on 4–12% Bis-Tris gels (Invitrogen) and stained by Blue
silver [34].
Statistical analysis
The Mann-Whitney test was performed with InStat software
(version 3.06, GraphPad, San Diego, CA) in Fig. S4 and repeated
measures ANOVA was used in Fig. 4B and 7D. The Student’s T-
test was used for Fig. 4D.
Results
HAMLET binds a-actinin-4 in cell extracts
To identify cellular targets involved in detachment, membrane-
associated proteins were isolated from A549 carcinoma cells. After
separation by SDS-PAGE and blotting, PVDF membranes were
overlaid with HAMLET. Bound HAMLET was visualized using
anti-a-lactalbumin and secondary HRP-conjugated antibodies
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band, which was identified by mass spectrometry as human a-
actinin-4. Matching peptides covered 19% of the a-actinin-4
sequence (Fig. 1A, Table S1) and 10% of the a-actinin-1 sequence.
The identity of the band was confirmed by Western blots using a-
actinin-4-specific polyclonal antibodies (Fig. 1A). Further evidence
of an interaction between a-actinin-4 and HAMLET in tumor
cells was obtained by co-immunoprecipitation of extracts from
HAMLET-treated A549 cells (15 minutes, 35 mM). Using a-
lactalbumin antibodies for precipitation of HAMLET and a-
actinin-4 antibodies for detection, a 96 kDa band was detected
(Fig. 1B).
As a-actinin-1 and a-actinin-4 are structural homologues and
share cellular functions, we subsequently examined if HAMLET
also binds to a-actinin-1 in tumor cells. Membranes with the co-
immunoprecipitation extracts were probed with an a-actinin-1
antibody, which detected a 96 kDa band at the same position as a-
actinin-4 (Fig. 1B).
The results show that HAMLET interacts with a-actinins in cell
extracts and in HAMLET-treated tumor cells.
Peptide mapping of binding sites for HAMLET on a-
actinin-4
The a-actinins are members of the spectrin superfamily,
forming an anti-parallel homodimer with one N-terminal actin-
binding domain at each end of the rod, a central rod domain with
four spectrin-like repeats, and a C-terminal, calmodulin-like
domain (Fig. 1C, [16,35,36]). The first and second spectrin
repeats interact with the cytoplasmic domain of b integrins [7].
HAMLET binding sites were identified using a synthetic peptide
library covering most of the a-actinin-4 sequence (each peptide was 20
amino acids long, with a 5 amino acid overlap). Binding of biotinylated
peptides to HAMLET was quantified using streptavidin-alkaline
phosphatase conjugates and interacting peptides were mapped onto
a cryo-EM reconstruction representation of smooth muscle a-actinin
(PDB code 1SJJ [26]) with MolMol software. Ten peptides with affinity
for HAMLET were identified (Fig. 1C,D): peptides 4, 6, 10 and 12 in
the actin-binding domain (CH1 and CH2), peptide 19 covering the
neck region between the actin-binding and the central rod domain and
peptide 24 corresponding to the first spectrin repeat on the central rod
domain (R1). Peptides 4, 10, 19 and 24 all face the cavity between the
actin-binding domain and the central rod domain, potentially forming
a combined binding site for HAMLET. In addition, HAMLET bound
to peptides 33 and 34 covering part of the proposed b integrin-binding
site, which consists of three loops on the first and second spectrin repeat
(R2) of a-actinin (Fig. 1C,D), [7]. Finally, HAMLET also bound to
peptides 53 and 59 in the C-terminal part of a-actinin-4. According to
the 3D structural model (Fig. 1C,D), all positive a-actinin-4 peptides
are exposed in the monomer as well as in the anti-parallel homodimer.
In the homodimer, peptides 53 and 59 of one monomer are localized
close to HAMLET-binding peptides on the adjacent monomer and
may form a combined binding site for HAMLET in the a-actinin-4
dimer (peptides 12, 19 and 24 for peptide 53 and peptides 4, 10 and 12
for peptide 59). The peptide map and visual inspection of the structures
(PDB codes 1SJJ and 1HML [37]) suggested that HAMLET may
potentially fit into the cavity between the actin-binding domain and the
central rod domain, linked by the flexible neck domain. In addition,
HAMLET may interact with part of the proposed b integrin-binding
site between spectrin repeats 1 and 2 (Fig. 1C,D).
The results indicate that HAMLET recognizes distinct,
functionally relevant a-actinin domains.
HAMLET alters the distribution of a-actinin-4 in tumor
cells
To further characterize the interaction between HAMLET and
a-actinin-4 in tumor cells, adherent A549 cells were incubated
with Alexa-Fluor 568-labeled HAMLET (35 mM, 1 hour), fixed,
stained for a-actinin-4 and inspected by confocal microscopy. In
untreated cells, a-actinin-4 staining in the cell periphery was
patchy or granular, indicating that a-actinin-4 accumulated in the
vicinity of certain membrane areas. After HAMLET treatment, a-
actinin-4 membrane staining was more uniform, indicating a loss
of membrane compartmentalization (Fig. 2A; for corresponding
light images see Fig. S2A). Large amounts of HAMLET were
internalized by the tumor cells and co-localization of HAMLET
and a-actinin-4 was detected at the cell periphery already after 15
minutes (3D z-stack images in Fig. 2B, Movie S1, for correspond-
ing light images see Fig. S2B). The cytoplasmic, trabecular staining
pattern was lost after HAMLET treatment, suggesting a loss of
cytoskeletal organization and a redistribution of a-actinin-4 to the
cell periphery (Fig. 2A).
Normal differentiated cells (HRTEC) showed a patchy or
granular a-actinin-4 staining pattern similar to the tumor cells and
more pronounced cytoplasmic staining along stress fibers (Fig. 2C,
for light images see Fig. S2C). Membrane staining was
accentuated in response to HAMLET (35 mM, 3 hours), but the
stress fibers remained visible even after HAMLET treatment and
there was no change in cell morphology or evidence of
detachment. The normal differentiated cells internalized very
small amounts of HAMLET and membrane co-localization of
HAMLET and a-actinin-4 was not observed (Fig. 2C).
The results show that HAMLET alters the cellular distribution
of a-actinin-4 in carcinoma cells, but not in normal, differentiated
cells and suggest that a-actinin-4 and HAMLET interact at the
membrane level in tumor cells.
HAMLET triggers rapid carcinoma cell detachment in
vitro
To address how HAMLET influences cell morphology and
detachment, several techniques were used. Adherent human lung
carcinoma or normal, differentiated cells were exposed to
Figure 1. HAMLET binds to a-actinin-4. A) HAMLET was shown to bind to a 96 kDa protein in the membrane fraction of carcinoma cell extracts in
a Far-Western blot with HAMLET. Bound HAMLET was detected using anti-a-lactalbumin antibodies. The 96 kDa band was identified as a-actinin-4 by
mass spectrometry (Profound analysis). The identity of the band was confirmed in a Western blot of membrane-associated proteins stained with
antibodies specific to a-actinin-4. B) Co-immunoprecipitation of HAMLET and a-actinin-4 and a-actinin-1 was detected in lysates from HAMLET-
treated carcinoma cells (15 minutes, 35 mM). HAMLET and associated proteins were immunoprecipitated with anti-a-lactalbumin antibodies and
lysates and precipitates were analyzed by Western blot. C) Peptide mapping of the interaction between HAMLET and a-actinin-4. The binding assay
with HAMLET and synthetic, 20 amino acid long, a-actinin-4 peptides detected 10 positive peptides. Positive peptides in a-actinin-4 from the actin-
binding domain are shown in green, one peptide in the hinge domain and one on the first spectrin repeat are shown in grey and two peptides near
the b integrin-binding site in blue. The interacting peptides in the a-actinin antiparallel homodimer are shown on top (PDB code 1SJJ, visualized in
MolMol). The enlargement illustrates HAMLET-binding peptides in an a-actinin monomer (residues 1-518). D) Table of a-actinin-4 peptides interacting
with HAMLET and their corresponding residue numbers, amino acid sequences, domains in a-actinin-4 and absorbance units (means 6 SEMs of 3
experiments).
doi:10.1371/journal.pone.0017179.g001
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confluence of adherent cell layers of carcinoma cells was observed
after 30 minutes, suggesting detachment (Fig. 3A). In addition, the
adherent cells changed morphology, from a distended flattened
appearance with pseudopods to a fully rounded shape with
occasional surface blebs, suggesting a loss of cytoskeletal integrity.
Detached cells, which were harvested from the supernatant,
retained this rounded morphology (data not shown). Normal
differentiated cells, in contrast, remained adherent with distended
morphology after 1 hour in the presence of HAMLET (35 mM,
Fig. 3A).
Cell detachment was further quantified as the loss of
hexosaminidase activity. Hexosaminidase is a lysosomal enzyme
catalyzing the degradation of glycosylated cellular constituents and
due to its widespread occurrence in cells of different origins,
hexosaminidase has been extensively used to measure cell numbers
[28]. Exposure of adherent carcinoma cells to HAMLET triggered
a dose- and time-dependent increase in cell detachment (Fig. 3B).
After 3 hours exposure to 35 mM of HAMLET, 37% of the cells
had detached, compared to 62% at 49 mM. Cell detachment
increased over time, from 33% after 1 hour to 62% after 6 hours
exposure to 35 mM of HAMLET. The cell viability of the
detached cells was also examined. After 3 hours of HAMLET
treatment, cells treated with 7 and 21 mM of HAMLET that had
detached showed 70 and 59% viability, suggesting that detach-
ment preceded death. At higher HAMLET concentrations
(35 mM) detached and adherent cells died rapidly (5% viability
of detached cells, Fig. S3).
Holographic imaging records 3D information of an unfixed
object in real time, based on interfering wave fronts from a laser
and was used to further characterize the cellular changes that
accompany the detachment process (Fig. 3C). After 15 minutes
exposure to HAMLET (35 mM), adherent human lung carcinoma
cells showed a reduction in surface area and an increase in
thickness and with evidence of membrane blebbing. After 1 hour,
the cells became smaller (from 547 to 341 mm
2) and thicker (from
2.33 to 4.27 mm) with a more rounded outline. The mean
eccentricity was reduced from 0.785 to 0.666 after HAMLET
exposure (1 hour, 35 mM).
The results show that HAMLET triggers rapid detachment of
tumor cells, but not of normal differentiated cells. In addition,
remaining tumor cells changed from a distended and flattened to a
rounded shape, consistent with loss of cytoskeletal organization.
Inhibition of cell detachment by a-actinin-4 peptides
The synthetic a-actinin-4 peptides used to map the interaction
of HAMLET with a-actinin-4 were also tested for inhibition of cell
detachment. HAMLET was pre-incubated with each peptide for
one hour, the mixture was added to A549 lung carcinoma cells
and cell morphology and detachment were examined (Fig. S4).
Peptides 12 and 34 reduced the rounding up (12: median values
32% vs. 70%, ns; 34: median values 38% vs. 70%, ** p,0.01) and
the detachment of the carcinoma cells (12: mean values 18% vs.
11%; 34: mean values 22% vs. 11%, ns). Peptides 4 and 24 also
inhibited cells from rounding up (4: median values 47% vs. 70%,
ns; 24: median values 27% vs. 70%, ** p,0.01) but the effects
might be non-specific due to aggregate formation of HAMLET
and peptide.
The results are consistent with the specificity of HAMLET for
a-actinin domains involved in cell adhesion.
Effects of a-actinin expression on cell detachment in
response to HAMLET
To examine if inhibition of a-actinin expression modifies tumor
cell detachment in response to HAMLET, A549 carcinoma cells
were transfected with a-actinin-4- and a-actinin-1-specific siRNAs
and knockdown was confirmed by RT-PCR and Western blots
(Fig. 4A) and detachment was quantified using the hexosaminidase
assay. The a-actinin-4- and a-actinin-1-specific siRNA-transfected
cell population detached to a greater extent in response to
HAMLET than non-transfected or control siRNA-transfected cells
(61% vs. 33%, *** p,0.001, 21 mM, 3 hours, Fig. 4B). Cells
transfected with both a-actinin-4- and a-actinin-1 siRNAs showed
a more pronounced detachment response to HAMLET (Fig. S5)
than cells treated with either siRNA alone. Furthermore, by
holographic imaging, a-actinin siRNA-treated carcinoma cells
were shown to be more round, to cover a smaller surface area and
have a greater thickness than control siRNA-transfected cells. In
response to HAMLET, cells with low a-actinin levels rounded up
faster and more (lower eccentricity) than control siRNA-transfect-
ed cells (data not shown).
To examine if a-actinin-4 overexpression reduces detachment
in response to HAMLET in carcinoma cells, A549 cells were
subsequently transfected with an a-actinin-4-GFP plasmid and a-
actinin-4-GFP expression was detected by live cell confocal
imaging. Cells transfected with an insert-free GFP control plasmid
were used as controls. Seventy-two hours after transfection, a-
actinin-4-GFP expression levels varied in the transfected cell
population, as determined by the GFP staining intensity (Fig. 4C).
There was a marked difference in the response to HAMLET
(21 mM, 3 hours) between a-actinin-4-GFP overexpressing cells
and cells with normal a-actinin-4 levels in the same population.
Cells overexpressing a-actinin-4-GFP were larger than surround-
ing cells, with a flattened morphology and their morphology
remained unchanged after 3 hours of HAMLET-treatment
(Fig. 4C). In the same sample, cells without detectable a-actinin-
4-GFP expression rounded up in response to HAMLET and
blebbing and nuclear condensation was observed. Similar changes
were observed in the GFP-control plasmid-transfected and
untransfected control cells (Fig. 4C). Cells which overexpressed
a-actinin-4-GFP showed reduced blebbing and nuclear conden-
sation (21 mM, 3 hours, ** p,0.01, Fig. 4D) compared to cells
with normal a-actinin-4 levels. These are two characteristics of the
cell death response to HAMLET [18]. After 6 hours exposure to
HAMLET, morphological changes occurred also in a-actinin-4-
GFP overexpressing cells, however.
Figure 2. HAMLET alters the distribution of a-actinin-4 in tumor cells. Carcinoma cells and normal cells were cultured on glass slides, fixed
and stained with antibodies specific for a-actinin-4 and examined by confocal microscopy. A) Granular a-actinin-4 staining along the cell membrane
in untreated cells changed to uniform staining after HAMLET exposure of carcinoma cells and accumulation of a-actinin-4 in membrane blebs (35 mM,
30 minutes, detached cells 1 hour). Means + SEMs of 3 experiments (1 hour). B) Co-localization of HAMLET with a-actinin-4 in carcinoma cells.
Carcinoma cells were treated with Alexa-Fluor 568-labeled HAMLET (red, 35 mM, 30 minutes) and stained with antibodies to human a-actinin-4
(green). HAMLET and a-actinin-4 co-localized at the cell periphery, especially where the cells started to contract (arrows). A Z-stack, 3D projection of a
carcinoma cell (15 min) showed co-localization at the cell periphery where the cell is attached to the glass slide. C) Normal differentiated cells (HRTEC)
showed accentuated membrane a-actinin-4 staining after HAMLET treatment (35 mM, 3 hours) but the actin stress fibres remained visible (means +
SEMs of 2 experiments).
doi:10.1371/journal.pone.0017179.g002
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17179The results show that a-actinin expression levels modify the
change in carcinoma cell morphology as well as detachment in
response to HAMLET.
HAMLET changes b1 integrin distribution and perturbs
focal adhesion kinase signaling
The effect of HAMLET on b1 integrin localization was
examined by confocal microscopy in A549 carcinoma cells
(Fig. 5A). Untreated, adherent carcinoma cells showed diffuse,
mainly cytoplasmic b1 integrin staining. After HAMLET exposure
(35 mM, 1 hour), remaining adherent cells had rounded up and
showed an increase in cytoplasmic b1 integrin staining, with
accumulation in large cytoplasmic aggregates in certain cells
(Fig. 5A). The detached, rounded cells showed weak b1-integrin
staining in the cell periphery.
Loss of b1 integrin binding to the extracellular matrix has
previously been shown to perturb FAK signaling and the MAPK/
ERK kinase pathway downstream of FAK is important for cell
survival and proliferation [38,39]. The effect of HAMLET-
induced detachment on FAK and ERK1/2 phosphorylation was
examined by Western blots, using antibodies specific for
phosphorylated FAK (pTyr397) and phosphorylated ERK1/2
(pThr202/Tyr204, ERK1 and pThr185/Tyr187, ERK2). Adher-
ent A549 carcinoma cells treated with HAMLET showed a
reduction in FAK phosphorylation after 30 minutes (21 and
35 mM) that was sustained for 3 hours. Cleavage of FAK was also
detected after 3 hours (Fig. 5B). HAMLET-induced detachment
also caused a reduction in ERK1/2 phosphorylation in A549
carcinoma cells after 30 minutes and 3 hours (21 and 35 mM) and
reduced total ERK1/2 levels after 3 hours (Fig. 5C). Cells
detached by EDTA treatment showed a slight reduction in FAK
phosphorylation but a slight increase in ERK phosphorylation
(Fig. S6).
The results suggest that detachment caused by HAMLET
involves the loss of integrin function and perturbs FAK and
ERK1/2 signaling.
Interactions with actin and b1 integrins
The changes in carcinoma cell morphology and behavior
suggested that cytoskeletal rearrangements might be involved,
consistent with the function of a-actinin-1 and -4 as cytoskeletal
crosslinkers and the binding of HAMLET to epitopes within the
previously identified actin- and b1 integrin-binding sites in the a-
actinin-1 and -4 isoforms (Fig. 1 and Fig. 6). In an attempt to
directly address if HAMLET disrupts the interaction between a-
actinin and F-actin, an actin binding protein spin down assay was
used. F-actin was isolated by ultra-centrifugation and proteins
bound to the filaments were detected by SDS-PAGE. a-Actinin
was shown to bind to F-actin both in the absence and presence of
HAMLET (Fig. S7), indicating that HAMLET did not disrupt the
interaction between a-actinin and F-actin under these conditions.
In addition, in an ELISA-based method, HAMLET was shown to
bind to a-actinin but binding of F-actin to a-actinin could not be
detected and for this reason inhibition by HAMLET could not be
measured. The conditions in the spin down assay are likely to be
unfavorable for maintaining the properties of the HAMLET
complex. For example, HAMLET triggers a rapid increase in
intracellular Ca
2+ [18] and high Ca
2+ levels reduce the binding
between a-actinin and F-actin [16]. Such a modification step
might be required before HAMLET can compete with F-actin for
binding to a-actinin. The lack of F-actin binding in the ELISA
may be due to missing cofactors, wrong pH or other unfavorable in
vitro conditions such that the actin filaments are disrupted under
conditions where HAMLET binds to a-actinin.
To examine if HAMLET perturbs the interaction between a-
actinin-4 and b1 integrins, total cell extracts from adherent
carcinoma cells were precipitated using anti-a-actinin-4 antibod-
ies, before or after HAMLET treatment (35 mM, 3 hours). Blots
stained with anti-b1 integrin antibodies show that a-actinin-4 and
b1 integrin still interact with each other in the presence of
HAMLET (Fig. 6B). This may indicate that binding of HAMLET
to peptide 33, which only partly covers the b1 integrin binding site
on a-actinin, does not directly hinder b1 integrin binding.
Detachment and cell viability
To investigate the relationship between a-actinin expression,
detachment and death, carcinoma cells were treated with a-
actinin-1 and -4 specific siRNAs for 72 hours and knockdown of
a-actinin-1 and -4 was confirmed by RT-PCR and Western blots
(Fig. 7A). The cells were detached, kept in suspension and cell
viability was quantified as trypan blue exclusion. After 22 hours in
suspension, no difference in cell viability was detected between the
cells with low a-actinin expression and non-transfected or control
siRNA-transfected cells (Fig. 7B). In parallel, the sensitivity of the
detached cells to HAMLET (35 mM, 3 hours) was quantified as a
function of a-actinin expression. The detached cells rapidly lost
viability (Fig. 7C) but no significant difference in cell death was
detected between a-actinin-1 and -4 siRNA-transfected cells with
low a-actinin levels and transfected control cells with normal a-
actinin levels (Fig. 7C).
The results suggest that the rapid cell death caused by
HAMLET does not depend on a-actinin expression. Furthermore,
detachment alone did not cause significant cell death during the
experiment.
To further examine if cell death and detachment may be
distinguished in adherent cells, the loss of viability was compared
between adherent a-actinin-1 and -4 specific siRNA-transfected
and control cells. Cells with low a-actinin levels were shown to die
to a greater extent than non-transfected or control siRNA-
transfected cells (53% vs. 27%, ** p,0.01, 35 mM, 3 hours,
Fig. 7D). Cells transfected with both a-actinin-4- and a-actinin-1-
specific siRNAs showed a more pronounced cell death response to
HAMLET (Fig. S5) than cells treated with either siRNA alone and
cells with low a-actinin levels also rounded up to a greater extent
than the cells with normal a-actinin levels (Fig. 7E). The results
Figure 3. Quantification of cell detachment in response to HAMLET. A) A549 carcinoma cells or normal kidney cells in primary culture
(HRTEC) were allowed to adhere to glass microscopy slides, treated with HAMLET (35 mM) and fixed. Cell confluence and morphology was examined
by confocal microscopy. HAMLET caused rapid rounding up and detachment of carcinoma cells (30 minutes, upper panels) but normal cells did not
change morphology or detach in response to HAMLET (1 hour, lower panels). B) The A549 cells detached in a time- and dose-dependent manner in
response to HAMLET (means 6 SEMs of 3 experiments). The top panel shows dose-dependent detachment after 3 hours of HAMLET treatment and
the lower panel shows both dose- and time-dependent detachment. Detachment was quantified by measuring hexosaminidase activity. C) The
morphological changes in tumor cells after HAMLET treatment were examined by real time holographic imaging (35 mM; HoloStudio
TM). After 15
minutes, membrane blebbing was observed followed by rounding up after 30 minutes and 1 hour. After 3 hours, the cells had shrunk and the




HAMLET Triggers Tumor Cell Detachment
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17179Figure 4. Altered a-actinin expression modifies cell detachment. A) a-Actinin siRNA knockdown was quantified by RT-PCR (means + SEM of 4
experiments) and Western blot. B) The hexosaminidase activity assay was used to examine the cell detachment after siRNA-treatment. In response to
HAMLET, tumor cell detachment was increased in cells with low a-actinin levels compared to cells transfected with negative control-siRNA or
untransfected cells (means 6 SEMs of 4 experiments, *** p,0.001). C) HAMLET response of cells overexpressing a-actinin-4-GFP was studied by live
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PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17179indicate that a-actinin expression modifies the death response to
HAMLET of adherent cells.
Discussion
HAMLET triggers rapid carcinoma cell detachment in vitro and
in bladder cancer patients, after topical administration [20]. This
study examined the molecular basis for carcinoma cell detachment
and identified a-actinins as HAMLET targets. a-Actinins link
integrins to the actin cytoskeleton by acting as a scaffold between
actin and b integrins, maintaining cytoskeletal architecture and cell
adhesion [3,9,14]. Using synthetic a-actinin-4 peptides, HAMLET
binding sites were mapped to the N-terminal actin-binding domain
and the proposed b integrin-binding central rod domain between
spectrin repeats 1 and 2, suggesting that HAMLET might impair
these essential interactions, [5,6,10]. Consistent with this effect,
HAMLET caused a rapid change from extended to round
morphology, suggesting a disruption of cytoskeletal architecture.
Inaddition,thecellslost b1integrinstaining and inhibitedFAKand
MEK/ERK signaling. The interaction of HAMLET with different
a-actinin domains might thus act to destabilize tumor cell adhesion.
In the present study, normal cells in primary culture were shown
not to detach or change their morphology in response to HAMLET
under conditions where cancer cells underwent such changes. a-
Actinin-4 is present both in tumor cells and normal differentiated
cells, suggesting that a-actinin-4 per se is not a cellular target
determining the increased HAMLET sensitivity of carcinoma cells.
T h er o l eo fa-actinin-4/a-actinin-1 in cancer development and
progression remains ambiguous and it is unclear if a-actinin-4/a-
actinin-1 might serve as cancer cell targets. a-Actinin-4 overexpres-
sion correlates with increased tumor invasiveness and metastasis in
pancreatic, esophageal, ovarian and lung carcinomas [40,41,42]. In
contrast, its expression was reduced in neuroblastomas and prostate
cancers and a mutated form of a-actinin-4 with decreased actin
binding affinity promoted lung cancer [43,44,45]. Human autosomal
dominant, gain of function mutations and a loss of function mouse
knockout both caused focal and segmental glomerulosclerosis but no
systemic tumorigenicity has been observed [46,47], suggesting that a-
actinin-4 variation per se may not be oncogenic. Recently it was
suggested that a-actinin-1 was involved in tumorigenesis as its
inhibition by RNAi in colon carcinioma cells enhanced tumor-free
survival [48]. In addition Quick and Skalli proposed that the levels of
a-actinin-1 and -4 are modulated in astrocytomas [15].
Several actin-binding sites have been mapped in the different a-
actinin isoforms. Honda et al. proposed amino acids 111-125 as an
actin-binding site in a-actinin-4 [9], corresponding to peptide 10
in our synthetic a-actinin-4 peptide library. Franzot et al. proposed
that residues 48–57, 123–147 and 153–172 form three indepen-
dent actin-binding sites in a-actinin-3 [6], corresponding to
synthetic a-actinin-4 peptides 4, 10 and 12, which all bound to
HAMLET. Based on these comparisons, we propose that
HAMLET binds to epitopes within the previously identified
actin-binding sites in the a-actinin-1 and -4 isoforms. The amino
acids covered by the positive peptides are also present in a-actinin-
1 but with other residue numbers. The amino acid sequences
covered by peptides 4, 6, 19 and 24 are identical in a-actinin-4
and -1 and the sequences covered by peptides 10 and 12 differ by
one residue, suggesting that the interactions of HAMLET with the
actin-binding sites may be similar in both isoforms. While
molecular details of these interactions remain to be defined, the
peptide map and visual inspection of the structures (PDB codes
1SJJ and 1HML) suggested that HAMLET may potentially fit into
the cavity between the actin-binding domain and the central rod
domain, linked by the flexible neck domain (Fig. 6A). Peptide 33
differed by three and peptide 34 by four residues, however,
suggesting that this region may have undergone divergent
evolution and that HAMLET interactions with the spectrin
repeats in a-actinin should be verified separately.
The involvement of a-actinin-4 and -1 in cell detachment was
supported by siRNA transfection as inhibition of a-actinin-4 and -
1 expression enhanced cell detachment and overexpression of a-
actinin-4 protected carcinoma cells from detaching in response to
HAMLET. In addition, overexpression of a-actinin-4-GFP
delayed the blebbing and nuclear condensation, which are
characteristics of HAMLET-induced cell death [18], seen in the
cells with normal a-actinin-4 levels. Detachment was identified as
a parameter independent of death, however, as transfected cells in
suspension, expressing low a-actinin-4 and -1 levels did not die to a
greater extent than untransfected cells. These cells responded to
HAMLET with similar rapid kinetics as cells with normal a-
actinin-expression, suggesting that a-actinin-4 and -1 are not
involved in the cell death response per se. In adherent cells with low
a-actinin levels, no increase in spontaneous cell death was
observed but cells with low a-actinin levels were more sensitive
to HAMLET-induced death than the cells with normal a-actinin
levels, consistent with the broader effects of a-actinins on receptors
and signaling.
Cell detachment has been suggested to promote cell death, as
cells in suspension are at a disadvantage as targets for growth
factors as well as essential nutritional components. Detachment
from the extracellular matrix may induce anoikis with apoptosis-
like cell characteristics in normal cells, whereas most tumor cells
proliferate also in the absence of anchorage-dependent signaling
[1,49]. On the other hand, disruption of the cytoskeletal
architecture in carcinoma cells induces amorphism; a form of
apoptosis. Both mechanisms are controlled by the mitochondria
through activation of the Bcl-2 protein family and death is
executed by effector caspases [1,2]. HAMLET has previously been
shown to trigger apoptosis and to interact directly with
mitochondria, leading to cytochrome c release, followed by
caspase activation, DNA fragmentation and annexin staining
[50,51]. Cell death in response to HAMLET is independent of this
pathway, however, as caspase 3-negative or Bcl-2 and Bcl-xl over-
expressing cells die with rapid kinetics and caspase inhibition does
not alter survival ([50], unpublished data). The mechanisms of
HAMLET-induced detachment and death observed in this study
are thus unrelated to apotosis, anoikis or amorphism.
Cell detachment has also been studied as an essential early step in
the metastatic spread of carcinoma cells. The hallmarks of metastatic
cells, include their ability to break through the basal lamina, infiltrate
blood vessels, exit the blood vessels, and form new tumors, through
finely regulated biomechanical interactions [52,53]. Recently, large
non-apoptotic blebs, with an amoeboid, highly motile cellular
phenotype were described and molecular studies suggested that Akt
signaling is involved and possibly small Rho-GTPases [54]. The
morphological changes of HAMLET-treated cells included the
formation of large blebs, suggesting that similar molecular mechanisms
might be involved. Our in vivo studies have shown that HAMLET
cell confocal microscopy. Rounding up in response to HAMLET (21 mM) was delayed compared to cells transfected with the GFP plasmid and cells
without the a-actinin-4-GFP plasmid. D) Overexpression of a-actinin-4-GFP in A549 cells delays blebbing and nuclear condensation caused by
HAMLET (21 mM, 3 hours, means + SDs of 3 experiments, ** p,0.01).
doi:10.1371/journal.pone.0017179.g004
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17179Figure 5. HAMLET changes b1 integrin distribution and disrupts FAK/ERK signaling. Carcinoma cells were cultured on glass slides, treated
with HAMLET and stained with antibodies specific for b1 integrins and examined by confocal microscopy. A) Reduction of b1 integrin staining
following HAMLET treatment (35 mM, 1 hour). Untreated carcinoma cells showed a diffuse staining pattern. After HAMLET treatment (35 mM, 1 hour)
the adherent cells remained b1 integrin-positive while the detached cells showed reduced b1 integrin staining. Adherent untreated and HAMLET-
treated cells and detached cells are shown with the corresponding light microscopy image. Means + SEMs of 3 experiments. B) HAMLET reduces FAK
phosphorylation (30 minutes) and induces FAK cleavage (3 hours) as shown by western blots using FAK and phospho-FAK (pTyr397) antibodies.
GAPDH was used as loading control. C) HAMLET reduces ERK1/2 phosphorylation (30 minutes) and induces ERK1/2 degradation (3 hours) as shown
by western blots using ERK1/2 and phospho-ERK1/2 antibodies. GAPDH was used as loading control.
doi:10.1371/journal.pone.0017179.g005
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urinary bladder cancers and that the majority of the shed cells are dead
[20]. Thus, HAMLET is not likelyto increase the risk for metastases, as
tumor cells die and detach with similar, rapid kinetics.
Maintaining the balance between the proliferative MEK/
ERK1/2 pathway and the apoptosis-promoting p38 and JNK
pathways is essential to control cell survival [55]. In a genome-
wide transcriptomic analysis of HAMLET-treated cells, we
recently identified the p38 pathway as a top-scoring pathway in
HAMLET-treated cells and showed that p38 inhibition delays cell
death (Storm et al, manuscript). This mode of HAMLET action is
consistent with the inhibition of MEK/ERK signaling observed in
the present study. Preliminary observations suggest that inhibition
of p38 also reduces tumor cell detachment in response to
HAMLET. Furthermore, the Rho family of small GTPases
influence the association of a-actinins with lamellipodia as well
as cell death and detachment in response to HAMLET
(unpublished data) and a-actinin-4 silencing decreases RhoA
mRNA levels [15,56]. In addition, a-actinins associate with ion
channels such as the L-type calcium channel and the Kv1.4 and
Kv1.5 potassium channels influencing the activation of ion
channels and intracellular Ca
2+ levels, which modulate the actin-
binding properties of a-actinins [16]. HAMLET activates rapid
ion fluxes and increases intracellular Ca
2+ levels in cancer cells
[18] and ion channel activation has recently been identified as a
key element of the lethal response to HAMLET (Storm et al,
manuscript). The rapid and strong detachment of tumor cells
exposed to HAMLET might thus reflect the combined activation
of ion channels, small GTPases and p38 signaling and a-actinin
may act by modulating several of these effects.
Figure 6. Schematic model of HAMLET-a-actinin interactions. A) The figure is based on information available in MolMol (PDB codes 1SJJ and
1HML) and on results from the peptide-binding assay and not on actual three-dimensional structural data of HAMLET bound to a-actinin-4. a-Actinin
forms a bridge between the cytoskeleton and the integrins through the actin- and b integrin-binding sites but also through vinculin and talin. By
binding to a-actinin, HAMLET may disrupt focal adhesions (enlargement, lower right). HAMLET interacts with the actin-binding domain of a-actinin
and fits into the pocket formed between the actin-binding domain and the first spectrin repeat. In addition, HAMLET binds adjacent to the b integrin-
binding site. B) Cell extracts from untreated or HAMLET-treated cells were used for co-immunoprecipitation with anti-a-actinin-4 antibodies. Blots
stained with anti-b1 integrin antibodies show that a-actinin-4 and b1 integrin still interact with each other in the presence of HAMLET.
doi:10.1371/journal.pone.0017179.g006
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Figure S1 HAMLET binds to a-actinin-4. HAMLET was
shown to bind to a 96 kDa protein in the membrane fraction of
carcinoma cell extracts in a Far-Western blot with HAMLET.
Bound HAMLET was detected using anti-a-lactalbumin antibod-
ies. The 96 kDa band was identified as a-actinin-4 by mass
spectrometry (Profound analysis).
(TIF)
Figure S2 Light images. Light images corresponding to
Figure 2. Tumor cells underwent morphological changes after
HAMLET treatment while normal differentiated cells remained
adherent with a flattened and distended morphology.
(TIF)
Figure S3 Cell viability in response to HAMLET. A)
Adherent cells were treated with HAMLET and the cell viability
of detached cells was quantified by trypan blue exclusion. After 3
hours of HAMLET treatment, cells treated with 7 and 21 mMo f
HAMLET that had detached showed 70 and 59% viability while
the cells treated with 35 mM of HAMLET showed 5% viability
(means + SEMs of 3 experiments). B) The cell viability of the
remaining adherent cells was also quantified by trypan blue
exclusion (means + SEMs of 2 experiments).
(TIF)
Figure S4 Inhibition of cell detachment by a-actinin-4
peptides. A, B) HAMLET was pre-incubated with the ten a-actinin-
4 peptides that bound to HAMLET in the peptide-binding assay. The
pre-incubated mixture or HAMLET alone was added to carcinoma
cells grown on glass slides and the morphology (A) and detachment (B)
were analyzed by light microscopy. Peptides 12 and 34 reduced the
rounding up and the detachment of the carcinoma cells. Peptides 4 and
24 also inhibited cells from rounding up but the effects might be non-
specific due to aggregate formation of HAMLET and peptide (A: 4
experiments; B: means + SEMs of 4 experiments; ** p,0.01).
(TIF)
Figure S5 Altered a-actinin expression modifies cell
detachment. A, B) a-Actinin siRNA knockdown was quantified by
RT-PCR(A, means +SEMs of3 experiments) and Westernblot (B).C)
The hexosaminidase activity assay was used to examine cell
detachment after siRNA-treatment. In response to HAMLET tumor
cell detachment was increased in cells with low a-actinin levels
compared to cells transfected with negative control-siRNA or
untransfected cells (means 6SEMs of 3 experiments). Cells transfected
with both a-actinin-4- and a-actinin-1-specific siRNA showed a more
pronounced detachment in response to HAMLET than cells treated
with either siRNA alone. D) By Trypan blue exclusion, tumor cell
death was increased in adherent cells with low a-actinin levels (means
6SEMs of 3 experiments). Cells transfected with both a-actinin-4- and
a-actinin-1-specific siRNA showed a more pronounced cell death in
response to HAMLET than cells treated with either siRNA alone.
(TIF)
Figure S6 Detachment and FAK/ERK phosphorylation.
A) Cells detached by EDTA treatment showed a slight reduction
in FAK phosphorylation as shown by western blots using FAK and
phospho-FAK (pTyr397) antibodies. GAPDH was used as loading
control. B) Cells detached by EDTA treatment showed a slight
increase in ERK phosphorylation as shown by western blots using
ERK1/2 and phospho-ERK1/2 antibodies. GAPDH was used as
loading control.
(TIF)
Figure S7 Actin-binding spin down assay. An actin-
binding spin down assay was performed to examine if HAMLET
disrupts the interaction of a-actinin with F-actin. After ultracen-
trifugation, F-actin forms a pellet (P) and actin-binding proteins
are also detected in these fractions. Proteins that do not interact
with actin remain in the supernatant (S).
(TIF)
Table S1 Identification of a-actinin-4 by mass spectrometry.
(DOC)
Movie S1 Co-localization of a-actinin-4 (green) and
Alexa 568-labelled HAMLET (red) in the periphery of
tumor cells. 3D projection of images collected as a z-stack.
Pictures were taken with a 0.37 mm interval and a 3D projection was
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